JOHNSON & JOHNSONJNJ
時価総額
$5157.9億
PER
医療・ヘルスケア製品の研究開発・製造・販売の最大手。DARZALEXを中心とした医薬品とACUVUEやTECNISなどのメドテック製品を展開。2024年にADC技術の臨床段階バイオ企業を約20億ドルで、IVL技術を持つ企業を335ドル/株で買収。約138,100人の従業員で世界各地に展開。
| 2011年 1月2日 | 2012年 1月1日 | 2012年 12月30日 | 2013年 12月29日 | 2014年 12月28日 | 2016年 1月3日 | 2017年 1月1日 | 2017年 12月31日 | 2018年 12月30日 | 2019年 12月29日 | 2021年 1月3日 | 2022年 1月2日 | 2023年 1月1日 | 2023年 12月31日 | 2024年 12月29日 | |
| Net earnings | 13,334 | 9,672 | 10,853 | 13,831 | 16,323 | 15,409 | 16,540 | 1,300 | 15,297 | 15,119 | 14,714 | 20,878 | 17,941 | 35,153 | 14,066 |
| Depreciation, Depletion and Amortization | 2,939 | 3,158 | 3,666 | 4,104 | 3,895 | 3,746 | 3,754 | 5,642 | 6,929 | 7,009 | 7,231 | 7,390 | 6,970 | 7,486 | 7,339 |
| Stock based compensation | 614 | 621 | 662 | 728 | 792 | 874 | 878 | 962 | 978 | 977 | 1,005 | 1,135 | 1,138 | 1,162 | 1,176 |
| Asset write-downs | - | - | 2,131 | 739 | 410 | 624 | 283 | 795 | 1,258 | 1,096 | 233 | 989 | 1,216 | 1,295 | 405 |
| Research and Development Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 483 | 1,841 |
| (Gain) on separation of Kenvue | - | - | - | - | - | - | - | - | - | - | - | - | - | 20,984 | - |
| Net gain on sale of assets/businesses | - | - | - | - | 2,383 | 2,583 | 563 | 1,307 | 1,217 | 2,154 | 111 | 617 | 380 | 117 | 226 |
| Deferred tax provision | 356 | -836 | -39 | -607 | 441 | -270 | -341 | 2,406 | -1,016 | -2,476 | -1,141 | -2,079 | -1,663 | -4,194 | -2,183 |
| Credit losses and accounts receivable allowances | 12 | 32 | 92 | -131 | -28 | 18 | -11 | 17 | -31 | -20 | 63 | -48 | -17 | - | 11 |
| Increase in accounts receivable | 207 | 915 | 9 | 632 | 247 | 433 | 1,065 | 633 | 1,185 | 289 | -774 | 2,402 | 1,290 | 624 | 406 |
| Increase in inventories | 196 | 715 | 1 | 622 | 1,120 | 449 | 249 | -581 | 644 | 277 | 265 | 1,248 | 2,527 | 1,323 | 1,128 |
| Increase in accounts payable and accrued liabilities | 20 | 493 | 2,768 | 1,821 | 955 | -3 | 656 | 2,725 | 3,951 | 4,060 | 5,141 | 2,437 | 1,098 | 2,346 | 1,621 |
| Decrease/(Increase) in other current and non-current assets | 574 | 1,625 | 2,172 | 1,806 | -442 | -65 | -18 | 411 | 275 | 1,054 | 3,704 | 1,964 | -687 | 3,480 | -1,717 |
| Increase (Decrease) in Other Operating Liabilities | 87 | 4,413 | -2,555 | 298 | -1,096 | 2,159 | -1,133 | 8,979 | -1,844 | 1,425 | 744 | -1,061 | -1,979 | 5,588 | 33 |
| Net cash flows from operating activities | 16,385 | 14,298 | 15,396 | 17,414 | 18,471 | 19,279 | 18,767 | 21,056 | 22,201 | 23,416 | 23,536 | 23,410 | 21,194 | 22,791 | 24,266 |
| Additions to property, plant and equipment | 2,384 | 2,893 | 2,934 | 3,595 | 3,714 | 3,463 | 3,226 | 3,279 | 3,670 | 3,498 | 3,347 | 3,652 | 4,009 | 4,543 | 4,424 |
| Proceeds from Sale of Productive Assets | 524 | 1,342 | 1,509 | 458 | 4,631 | 3,464 | 1,267 | 1,832 | 3,203 | 3,265 | 305 | 711 | 543 | 358 | 675 |
| Acquisitions, net of cash acquired | 1,269 | 2,797 | 4,486 | 835 | 2,129 | 954 | 4,509 | 35,151 | 900 | 5,800 | 7,323 | 60 | 17,652 | - | 15,146 |
| Purchases of in-process research and development assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 470 | 1,783 |
| Purchases of investments | 15,788 | 29,882 | 13,434 | 18,923 | 34,913 | 40,828 | 33,950 | 6,153 | 5,626 | 3,920 | 21,089 | 30,394 | 32,384 | 10,906 | 1,726 |
| Sales of investments | 11,101 | 30,396 | 14,797 | 18,058 | 24,119 | 34,149 | 35,780 | 28,117 | 4,289 | 3,387 | 12,137 | 25,006 | 41,609 | 19,390 | 2,462 |
| Credit support agreements activity, net | - | - | - | - | - | - | - | - | - | - | -987 | 214 | -249 | -2,963 | 1,517 |
| Other (including capitalized licenses and milestones) | 38 | 778 | -38 | 266 | 299 | 103 | 123 | 234 | 464 | -44 | 521 | 508 | 229 | -12 | 174 |
| Net cash (used by)/from investing activities | -7,854 | -4,612 | -4,510 | -5,103 | -12,305 | -7,735 | -4,761 | -14,868 | -3,167 | -6,194 | -20,825 | -8,683 | -12,371 | 878 | -18,599 |
| Dividends to shareholders | 5,804 | 6,156 | 6,614 | 7,286 | 7,768 | 8,173 | 8,621 | 8,943 | 9,494 | 9,917 | 10,481 | 11,032 | 11,682 | 11,770 | 11,823 |
| Repurchase of common stock | 2,797 | 2,525 | 12,919 | 3,538 | 7,124 | 5,290 | 8,979 | 6,358 | 5,868 | 6,746 | 3,221 | 3,456 | 6,035 | 5,054 | 2,432 |
| Proceeds from short-term debt | 7,874 | 9,729 | 3,268 | 1,411 | 1,863 | 2,416 | 111 | 869 | 80 | 39 | 3,391 | 1,997 | 16,134 | 13,743 | 15,277 |
| Repayment of short-term debt | 6,565 | 11,200 | 6,175 | 1,397 | 1,267 | 1,044 | 2,017 | 1,330 | 2,479 | 100 | 2,663 | 1,190 | 6,550 | 22,973 | 9,463 |
| Proceeds from Issuance of Long-Term Debt | 1,118 | 4,470 | 45 | 3,607 | 2,098 | 75 | 12,004 | 8,992 | 5 | 3 | 7,431 | 5 | 2 | - | 6,660 |
| Repayment of long-term debt | 32 | 16 | 804 | 1,593 | 1,844 | 68 | 2,223 | 1,777 | 1,555 | 2,823 | 1,064 | 1,802 | 2,134 | 1,551 | 1,453 |
| Proceeds From The Exercise Of Stock Options And Excess Tax Benefits | - | - | 2,720 | 2,649 | 1,782 | 1,295 | 1,189 | 1,062 | 949 | 954 | 1,114 | 1,036 | 1,329 | 1,094 | 838 |
| Credit support agreements activity, net | - | - | - | - | - | - | - | - | - | - | -333 | 281 | -28 | -219 | 272 |
| Settlement of convertible debt acquired from Shockwave | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 970 |
| Proceeds From Issuance Of Long-Term Debt, Transferred In Business Separation | - | - | - | - | - | - | - | - | - | - | - | - | - | 8,047 | - |
| Proceeds from Kenvue initial public offering | - | - | - | - | - | - | - | - | - | - | - | - | - | 4,241 | - |
| Cash transferred to Kenvue at separation | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,114 | - |
| Other | - | - | -83 | 56 | - | -57 | -15 | -188 | -148 | 575 | -294 | 114 | 93 | -269 | -38 |
| Net cash used by financing activities | -4,980 | -4,452 | -20,562 | -6,091 | -12,260 | -10,846 | -8,551 | -7,673 | -18,510 | -18,015 | -6,120 | -14,047 | -8,871 | -15,825 | -3,132 |
| Effect of exchange rate changes on cash and cash equivalents | - | - | - | - | - | - | - | - | - | -9 | 89 | -178 | -312 | -112 | -289 |
| Increase/(Decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | - | -802 | -3,320 | 502 | -360 | 7,732 | 2,246 |
| Interest | - | - | 616 | 596 | 603 | 617 | 730 | 960 | 1,049 | 995 | 904 | 990 | 982 | 1,836 | 1,990 |
| Interest, net of amount capitalized | 491 | 576 | - | 491 | 488 | 515 | 628 | 866 | 963 | 925 | 841 | 941 | 933 | 1,766 | 1,911 |
| Income Taxes Paid | 2,442 | 2,970 | 2,507 | 3,155 | 3,536 | 2,865 | 2,843 | 3,312 | 4,570 | 4,191 | 4,619 | 4,768 | 5,223 | 8,574 | 6,714 |
| Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds | 673 | 433 | 615 | 743 | 1,170 | 1,196 | 2,043 | 2,062 | 2,095 | 1,736 | 1,937 | 1,811 | 2,114 | 1,435 | 1,551 |
| Fair value of assets acquired | - | 3,025 | 19,025 | 1,028 | 2,167 | 1,174 | 4,586 | 36,937 | 1,047 | 7,228 | 7,755 | 61 | 18,710 | - | 16,091 |
| Fair value of liabilities assumed | - | 228 | 1,204 | 193 | 38 | 220 | 77 | 1,786 | 148 | 1,418 | 432 | 1 | 1,058 | - | 1,632 |
| Net cash paid for acquisitions (Note 18) | - | 2,797 | 17,821 | 835 | 2,129 | 954 | 4,509 | 35,151 | 899 | 5,810 | 7,323 | 60 | 17,652 | - | 14,459 |